When was LABORATOIRE X.O acquired by STANLEY CAPITAL PARTNERS?

LABORATOIRE X.O was acquired by STANLEY CAPITAL PARTNERS in 2022.

What was the revenue of LABORATOIRE X.O at the time of the deal?

The revenue of LABORATOIRE X.O at the time of the deal is estimated to be in the range of 50M - 100M EUR.

How is the data for the LABORATOIRE X.O acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORATOIRE X.O deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/laboratoire-xo-accueille-a-bras-ouverts-stanley-capital-partners-1868294

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaLABORATOIRE X.O

10/2022

LABORATOIRE X.O acquired by STANLEY CAPITAL PARTNERS

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs REV 50M - 100M EUR

Context

Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.

It is worth noting that the fund Novalpina Capital took control of Laboratoire X.O through an LBO in 2020.

LABORATOIRE X.O, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2015, Laboratoire X.O is a specialty pharmaceutical company focused on acquiring and revitalizing mature drug brands (Legacy Brands) from "Big Pharma." It operates an asset-light model, outsourcing production while managing 21 Market Authorizations (MA). Its portfolio includes prescription drugs and a growing Over-The-Counter (OTC) division, with key brands like Prexidine (mouthwash).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with LABORATOIRE X.O

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
11/2020	NOVALPINA CAPITAL	LABORATOIRE X.O	FRANCE	Generics / Labs

REFERENCES

Revenue range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORATOIRE X.O by STANLEY CAPITAL PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: stanley capital partners